Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    18160686 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: bevacizumab;   Drug: Paclitaxel
2 Completed Polymorphism Interaction to Predict Bevacizumab Efficacy
Condition: Metastatic Breast Cancer
Intervention:
3 Not yet recruiting MEtronomic TrEatment Option in Advanced bReast cAncer
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Vinorelbine
4 Active, not recruiting Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Apatinib
5 Active, not recruiting Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: low-dose-bevacizumab/pemetrexed;   Drug: Treatment of physician's choice
6 Completed A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Trastuzumab, Docetaxel;   Drug: Trastuzumab, Docetaxel, Bevacizumab;   Drug: Trastuzumab+Docetaxel+NPLD;   Drug: Trastuzumab+Docetaxel+NPLD+Bevacizumab

Study has passed its completion date and status has not been verified in more than two years.